Ignite Creation Date:
2024-05-06 @ 9:58 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03121599
Status:
TERMINATED
Last Update Posted:
2020-08-11
First Post:
2017-04-17
Brief Title:
18F-FLT PETCT in Pediatrics With Myeloproliferative Neoplasms
Sponsor:
Hamad Medical Corporation
Organization:
Hamad Medical Corporation
Study Overview
Official Title:
A Study of 18F-FLT Positron Emission Tomography PETComputed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms
Status:
TERMINATED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Delayed study materials poor recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group in terms of diagnosis staging and monitoring response to therapy As well as evaluating FLT-PET as a novel non-invasive technique in cases with MPN and its role in comparison to the standard bone marrow biopsy with regard to disease diagnosis assessment of disease activity detection of transformation monitoring of treatment response and grading of fibrosisFurthermore we aim to study the association of FLT-PET uptake patterns with different genetic makeup JAK2 CALR positive MPL or Triple negative disease or allele burden in cases of Pre-PMF with the ability of FLT-PET to differentiate between Pre-PMF and ET
Although MPNs are diseases of elderly MPN is diagnosed in younger age groups in a considerable number of cases Since most of the available data as well as current WHO classification criteria emphases on the average MPN patients who range in age between 55 and 65 years Less consistent data are available in the groups of patients presenting below this median age such as children and younger adults which were planning to reveal
Although MPNs are diseases of elderly MPN is diagnosed in younger age groups in a considerable number of cases Since most of the available data as well as current WHO classification criteria emphases on the average MPN patients who range in age between 55 and 65 years Less consistent data are available in the groups of patients presenting below this median age such as children and younger adults which were planning to reveal
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None